This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bantick, R. A. Articles by Grasby, P. M. Search for Related Content PubMed PubMed Citation Articles by Bantick, R. A. Articles by Grasby, P. M. Social Bookmarking                         What's this?

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

MRC Cyclotron Unit, The Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; alexander.bantick{at}ic.ac.uk

J. F. W. Deakin

Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK

P. M. Grasby

MRC Cyclotron Unit, The Hammersmith Hospital, London

Increasing attention is being directed towards the role of the serotonergic system in the neurochemistry of schizophrenia and antipsychotic drug treatment. This review considers the 5-HT1A receptor in this context. In patients with schizophrenia, the majority of post-mortem studies have reported increases in 5-HT1A receptor density in the prefrontal cortex in the approximate range 15–80%. Although the pathophysiological significance of this finding is unclear, given the location of a major proportion of these receptors on pyramidal cells, it may reflect an abnormal glutamatergic network. In terms of drug treatment, 5-HT1A agonists clearly display anticataleptic activity in rats. In addition, 5-HT1A agonists consistently increase dopamine release in the prefrontal cortex in rodents, which is an effect that might be predicted to improve negative symptoms. 5-HT1A agonists augment classical neuroleptics in some rat models of antipsychotic action and may be capable of modulating the glutamatergic network therapeutically. Despite the encouraging preclinical data, there is a paucity of clinical studies of 5-HT1A agonist augmentation of neuroleptics in the treatment of schizophrenia. However, the clinical relevance may be clarified by the atypical antipsychotic drugs clozapine, quetiapine and ziprasidone which combine D2 receptor antagonism and 5-HT1A agonism. In conclusion, given the increased prefrontal 5-HT1A receptor density in the illness, and the anticataleptic activity of 5-HT1A agonists combined with their ability to evoke prefrontal dopamine release, there is now a sufficient rationale to examine thoroughly the role of the 5-HT1A receptor in schizophrenia and antipsychotic drug treatment.

Key Words: atypical antipsychotic • dopamine • glutamate • 5-HT1A receptor • review • schizophrenia

Journal of Psychopharmacology, Vol. 15, No. 1, 37-46 (2001)
DOI: 10.1177/026988110101500108


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Z. Li, A. J. Prus, J. Dai, and H. Y. Meltzer Differential Effects of M1 and 5-Hydroxytryptamine1A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 948 - 955. [Abstract] [Full Text] [PDF]

				L Dahan, H Husum, O Mnie-Filali, J Arnt, P Hertel, and N Haddjeri Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour J Psychopharmacol, March 1, 2009; 23(2): 177 - 189. [Abstract] [PDF]

				L. Wang, C. Fang, A. Zhang, J. Du, L. Yu, J. Ma, G. Feng, Q. Xing, and L. He The --1019 C/G polymorphism of the 5-HT1A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients J Psychopharmacol, November 1, 2008; 22(8): 904 - 909. [Abstract] [PDF]

				A. Rauch, G. Rainer, and N. K. Logothetis The effect of a serotonin-induced dissociation between spiking and perisynaptic activity on BOLD functional MRI PNAS, May 6, 2008; 105(18): 6759 - 6764. [Abstract] [Full Text] [PDF]

				Z. Gu, Q. Jiang, and Z. Yan RGS4 Modulates Serotonin Signaling in Prefrontal Cortex and Links to Serotonin Dysfunction in a Rat Model of Schizophrenia Mol. Pharmacol., April 1, 2007; 71(4): 1030 - 1039. [Abstract] [Full Text] [PDF]

				M. van den Buuse and A. Gogos Differential Effects of Antipsychotic Drugs on Serotonin-1A Receptor-Mediated Disruption of Prepulse Inhibition J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1224 - 1236. [Abstract] [Full Text] [PDF]

				M. Wittmann, O. Carter, F. Hasler, B. R. Cahn, U. Grimberg, P. Spring, D. Hell, H. Flohr, and F. X. Vollenweider Effects of psilocybin on time perception and temporal control of behaviour in humans J Psychopharmacol, January 1, 2007; 21(1): 50 - 64. [Abstract] [PDF]

				G. P. Reynolds, B. Arranz, L. A. Templeman, S. Fertuzinhos, and L. San Effect of 5-HT1A Receptor Gene Polymorphism on Negative and Depressive Symptom Response to Antipsychotic Treatment of Drug-Naive Psychotic Patients Am J Psychiatry, October 1, 2006; 163(10): 1826 - 1829. [Abstract] [Full Text] [PDF]

				E. Y. Yuen, Q. Jiang, P. Chen, Z. Gu, J. Feng, and Z. Yan Serotonin 5-HT1A Receptors Regulate NMDA Receptor Channels through a Microtubule-Dependent Mechanism J. Neurosci., June 8, 2005; 25(23): 5488 - 5501. [Abstract] [Full Text] [PDF]

				R. McQuade, M. M. Leitch, S. E. Gartside, and A. H. Young Effect of chronic lithium treatment on glucocorticoid and 5-HT1A receptor messenger RNA in hippocampal and dorsal raphe nucleus regions of the rat brain J Psychopharmacol, December 1, 2004; 18(4): 496 - 501. [Abstract] [PDF]

				R. A. Bantick, A. J. Montgomery, C. J. Bench, T. Choudhry, N. Malek, P. J. McKenna, D. J. Quested, J. F. W. Deakin, and P. M. Grasby A Positron Emission Tomography Study of the 5-Ht1A Receptor in Schizophrenia and during Clozapine Treatment J Psychopharmacol, September 1, 2004; 18(3): 346 - 354. [Abstract] [PDF]

				D. A. Cruz, S. M. Eggan, E. C. Azmitia, and D. A. Lewis Serotonin1A Receptors at the Axon Initial Segment of Prefrontal Pyramidal Neurons in Schizophrenia Am J Psychiatry, April 1, 2004; 161(4): 739 - 742. [Abstract] [Full Text] [PDF]

				X. Cai, Z. Gu, P. Zhong, Y. Ren, and Z. Yan Serotonin 5-HT1A Receptors Regulate AMPA Receptor Channels through Inhibiting Ca2+/Calmodulin-dependent Kinase II in Prefrontal Cortical Pyramidal Neurons J. Biol. Chem., September 20, 2002; 277(39): 36553 - 36562. [Abstract] [Full Text] [PDF]

				J. Tauscher, S. Kapur, N. P. L. G. Verhoeff, D. F. Hussey, Z. J. Daskalakis, S. Tauscher-Wisniewski, A. A. Wilson, S. Houle, S. Kasper, and R. B. Zipursky Brain Serotonin 5-HT1A Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635 Arch Gen Psychiatry, June 1, 2002; 59(6): 514 - 520. [Abstract] [Full Text] [PDF]

				E. A. Rabiner, R. N. Gunn, M. R. Wilkins, E. Sedman, and P. M. Grasby Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride J Psychopharmacol, May 1, 2002; 16(3): 195 - 199. [Abstract] [PDF]